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Acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease
(COPD) are associated with significant healthcare costs and contribute to the progress of the
disease. Although a number of factors may trigger these episodes, between 40% and 60% are
bacterial in nature. Antimicrobial therapy can be effective in treating exacerbations, leading
to improved peak expiratory flow rates, fewer hospitalizations, lower relapse rates, and
greater clinical success. Evidence suggests that short-course antimicrobial therapy can be as
effective as standard duration therapy (>7 days) in treating exacerbations. Randomized trials
have shown that clinical and bacteriological success rates are comparable with both 5-day and
standard antibiotic courses. Furthermore, 5-day fluoroquinolone therapy is associated with
faster recovery, fewer relapses, prolonged duration between episodes, and less hospitalization
when compared with standard therapy. Both moxifloxacin and gemifloxacin have received
FDA-approval for 5-day therapy in AECB.
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Approximately 13 million Americans suffer from chronic
bronchitis or chronic obstructive pulmonary disease
(COPD).1 Acute exacerbations of chronic bronchitis (AECB)
affect many of these individuals and account for an
estimated 12 million physician visits annually.1 Exacerba-
tions lead to declines in lung function, cause significant
morbidity and mortality, accelerate disease progression,1e3
and significantly lower the quality of life,4 including an
increase in the risk of being housebound.5,6
The cardinal symptoms of exacerbations are increased
cough, dyspnea, increased sputum volume, and increased
sputum purulence.7 COPD patients have between 1 and 3
exacerbation episodes per year,1 and the frequency may be
associated with disease severity.2,8
Etiology of exacerbations
Environmental factors such as air pollutants, allergens,
temperature changes, or irritants (i.e., dust and cigarette
smoke) can precipitate an exacerbation. Comorbid condi-
tions such as congestive heart failure or pulmonary embo-
lism may aggravate or mimic an exacerbation, while lack of
compliance with therapy has also been implicated in some
patients.1 However, infections are the most common
trigger, with bacterial or viral pathogens accounting for 80%
of AECB episodes.9,10
Bacterial pathogens occur in 40e60% of AECB sputum
samples,9 and require appropriate and timely antimicrobial
therapy. Patients who are elderly or with multiple comorbid
conditions, those who have more purulent sputum or
patients with worsening COPD, are more likely to have
bacterial infections.11,12 In many cases, bacterial exacer-
bations are secondary to viral infections, and 25% of
patients may have a viral/bacterial coinfection.1,10
Gram-negative bacteria are more likely to be involved in
AECB, with Haemophilus influenzae accounting for 50% of
all bacterial exacerbations.11,10,13 However, Moraxella
catarrhalis causes some AECBs, and Pseudomonas aerugi-
nosa and other Gram-negative bacilli, such as Enter-
obacteriaceae, are more prevalent in patients with severe
impairment of lung function.11,13 Among Gram-positive
bacteria, Streptococcus pneumoniae is the most common,
and S. pneumoniae and M. catarrhalis have been found in
approximately 30% of isolates obtained from patients with
exacerbations. Atypical respiratory pathogens, including
Chlamydophila pneumoniae, occur in 5e10% of AECB.9
Resistance is an important issue in AECB, with both
b-lactam and macrolide resistance occurring amongcausative pathogens. Further, multidrug-resistant bacteria
are common among patients with severe acute exacerba-
tions requiring intubation and mechanical ventilation.1
Likely causative pathogens vary according to the
severity of the underlying COPD and the degree to which
the lung function is impaired. In patients with mild-to-
moderate COPD, H. influenzae and S. pneumoniae are the
most common pathogens implicated in exacerbations.
Staphylococcus aureus and Gram-negative bacteria, such as
P. aeruginosa and Enterobacteriaceae species, predomi-
nate in patients who experience severe exacerbations and
have a forced expiratory volume in 1 s (FEV1)  35%.11,13
Approximately 30e50% of AECB are associated with a viral
infection.9,10 These infections may exacerbate existing
inflammation in patient airways and predispose individuals
to secondary bacterial infection.6,14,15
Antimicrobial therapy in the management of
AECB
Successful management of AECB entails achievement of
four goals: rapidly resolving symptoms, preventing relapse,
prolonging the time between exacerbations, and inter-
rupting the vicious cycle of recurrent infection induced lung
damage.1 A number of guidelines have established treat-
ment recommendations for AECB. The American College of
Physicians and the American College of Chest Physicians
endorse the benefit of antibiotic therapy,16 especially for
patients with more severe exacerbations.16 Evidence indi-
cates that antimicrobial therapy can be effective in treat-
ing exacerbations, leading to improved peak expiratory
flow rates, fewer hospitalizations, lower relapse rates, and
greater clinical success.7,17,18 Current guidelines for anti-
microbial therapy in AECB include those from the Global
Initiative for Chronic Obstructive Lung Disease (GOLD), the
American Thoracic Society, the Canadian Thoracic Society
and the Canadian Infectious Disease Society, the European
Respiratory Society, and a consensus statement formulated
by a number of Spanish medical societies.1,19e21
Selection of effective antimicrobial therapy is critical.
Some evidence suggests that use of inappropriate antibi-
otics may result in poor outcomes and greater likelihood of
relapse.17 The Council for Appropriate and Rational Anti-
biotic Therapy (CARAT) criteria recommend that selection
of antibiotic treatment be supported with strong clinical
evidence, such as data from randomized, double-blind,
controlled multicenter trials.22 Table 1 presents Canadian
guidelines for first-line antimicrobial treatment and alter-
natives for treatment failure in AECB.1 These guidelines
represent a joint effort by the Canadian Thoracic Society
Table 1 Initial empiric therapy in outpatients with acute bacterial exacerbations of chronic bronchitis.
Risk group Basic clinical state Symptoms and risk factors Probable pathogens First choice Alternatives for treatment
failure
I Chronic bronchitis without
risk factors (simple)
Increased cough and sputum,
sputum purulence, and
increased dyspnea
Haemophilus influenzae,
Haemophilus spp. Moraxella
catarrhalis, Streptococcus
pneumoniae
2nd-generation macrolide,
2nd- or 3rd-generation
cephalosporin, amoxicilin,
doxycycline, TMP-SMX
Fluoroquinolone, b-lactam/
b-lactamase inhibitor
II Chronic bronchitis with risk
factors (complicated)
As in group I plus 1 of the
following:
 FEV1 < 50% predicted
 >4 exacerbations/yr
 Cardiac disease
 Use of home oxygen
 Chronic oral steroid use
 Antiobiotic use in the
past 3 mo
As in group I plus Klebsiella
spp. þ other Gram-negative
pathogens Increased
probability of b-lactam
resistance
Fluoroquinalone or b-lactam/
b-lactamase inhibitor
May require parenteral therapy
Consider referral to a specialist
or hospital
III Chronic suppurative
bronchitis
As in group II with constant
purulent sputum
 Some have bronchiectasis
 FEV1 < 35% predicted
 Use of home oxygen
 Multiple risk factors (e.g.,
frequent exacerbations
and FEV1 < 50% predicted)
As in group II plus Pseudomonas
aeruginosa and multiresistant
Enterobacteriaceae
Ambulatory patients: tailor
treatment to airway pathogen
P aeruginosa common
(ciprofloxacin)
Hospitalized patients:
parenteral therapy usually
required
e
FEV1: forced expiratory volume in 1 s; TMP-SMK: trimethoprim-sulfamethoxazole. Reproduced with permission from Balter MS, La Forge J, Low DE Mandell L, Grossman RF, and the Chronic
Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of
chronic bronchitis: executive summary. Can Respir J 2003; 10:248e58.
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Duration of fluoroquinolone therapy in AECB and COPD 1399and the Canadian Infectious Disease Society.1 Patients are
stratified according to risk factors, with antibiotic recom-
mendations for each group.1
P. aeruginosa and other Gram-negative bacilli are more
common in patients who have frequent exacerbations,
chronic use of oral steroids, or severe pulmonary disease
(GOLD IV),11,13,23 such as Group III patients with AECB
(Table 1) and patients with more-advanced exacerbations
of COPD.24 In a recent study of hospitalized patients with
exacerbations of COPD, Garcia-Vidal and colleagues iden-
tified the BODE (body mass index, airflow obstruction,
dyspnea, exercise capacity) index ([odds ratio] OR 2.18;
95% confidence interval [CI], 1.26e3.78; P Z 0.005),
admissions in the previous year (OR 1.65; 95% CI,
1.13e2.43; P Z 0.005), systemic steroid treatment (OR
14.7; 95% CI, 2.28e94.8; P Z 0.01), and previous isolation
of P. aeruginosa (OR 23.1; 95% CI, 5.7e94.3; P < 0.001) as
risk factors for P. aeruginosa infection.23 Many of these
organisms are resistant to traditional first-line agents, such
as amoxicillin, doxycycline, trimethoprim/sulfamethox-
azole, azalides, and macrolides.25 Fluoroquinolones
(ciprofloxacin, and high-dose levofloxacin 750 mg) have
been recommended as the agent of choice when these
pathogens are identified in patients with AECB.1
Short-course therapy versus standard therapy
Duration of antimicrobial treatment is a critical decision.
Short-course therapy (defined as 5 days) may have
a number of advantages over standard therapy (>7 days),
including improved speed of recovery, shortened time to
symptom improvement, decreased relapse rate, and pro-
longed intervals between recurrences. Additionally, short-
course therapy may reduce the risk of adverse events and
the pressure that drives bacterial resistance as a result of
shorter exposure to antibiotics.26,27 Reduced hospital
admission rates, hospital lengths of stay, and healthcare
costs have also been demonstrated with short-course
therapy.26,28e32 Further, there may also be an impact on
the long-term course of the disease.32 In patients with
pseudomonas infections, mainly nosocomial infections, the
current recommendations are to receive antibiotics for up
to 15 days. Longer duration of therapy is associated with
reduced failure rates.33
A meta-analysis of 7 randomized controlled trials, with
a total patient population of 3083, compared different
treatment durations of the same antibiotic regimen. The
short-duration treatment proved as effective as and safer
than long-duration antimicrobial therapy in patients with
AECB.26 Short-course therapy was associated with fewer
adverse events as compared with standard, longer duration
treatment.26 A second meta-analysis involving 21 double-
blind studies and 10,698 patients also found that clinical
cure rates, at both early and late follow-up, and bacteri-
ological cure rates observed with short-course therapy
were comparable to those achieved with conventional
duration therapy in patients with mild-to-moderate exac-
erbations.34 Similar observations were found for early cure
when different treatment durations of the same antibiotic
were compared. The authors suggested that a shorter
course of antibiotic treatment may enhance complianceand reduce antibiotic costs, and further recommended that
antibiotic treatment duration be no longer than 5 days,
regardless of antibiotic class, in patient with mild-to-
moderate exacerbations of COPD or chronic bronchitis.34
Short-course therapy with cephalosporins,
b-lactams, and macrolides
A trial investigating the efficacy and safety of a 5-day
course of pharmacokinetically-enhanced amoxicilline
clavulanate (2000/125 mg bid) compared with a 7-day
course of conventional amoxicillineclavulanate (875/
125 mg bid) in AECB found that the shorter course was as
effective clinically in the per-protocol (PP) population as
the longer course regimen, with a clinical success rate of
93.0% and 91.2%, respectively.35 Further, bacteriological
success was achieved in 76.7% and 73.0%, respectively.35 A
once-daily, 5-day course of clarithromycin extended-
release (1000 mg) was compared to 7-day clarithromycin
regular-release taken twice daily (500 mg) for AECB. As
with the other trials, results were similar in both groups e
clinical cures among evaluable patients were 84% in both
extended- and regular-release groups. The bacteriological
cure rates were 87% and 89%, respectively, and overall
target pathogen eradication rates were 88% and 89%,
respectively.36 However, 5-day clarithromycin extended-
release was better tolerated and caused statistically
significantly fewer drug-related adverse events due to
abnormal taste than the regular-release formulation (3%
and 8%, respectively, P Z 0.012).36
Short-course fluoroquinolone therapy
The respiratory fluoroquinolones (levofloxacin, moxi-
floxacin, and gemifloxacin) exhibit a broadespectrum
activity against most pathogens associated with AECB.28
Fluoroquinolones have been recommended as first-line
treatment for AECB in patients with chronic bronchitis
complicated by comorbid illness, severe COPD with
a FEV1 < 50%, patients >65 years, or recurrent exacerba-
tions (Table 1).1
Clinical studies have demonstrated comparable, and in
some cases, superior efficacy for short-course, 5-day fluo-
roquinolone therapy to that of standard therapy in AECB, as
measured by both clinical and bacteriological outcomes. In
a randomized, double-blind study of a 5-day course of
500 mg levofloxacin qd compared with the 7-day, 500 mg qd
regimen in 532 patients with AECB, the clinical success rates
in the PP analysis were 82.8% for the 5-day regimen and
84.4% for the 7-day regimen. Bacteriological eradication
rates were also similar at 82.1% and 83.2%, respectively.37
In a randomized, noninferiority study, 369 patients with
severe AECB were randomized to receive either high-dose
levofloxacin therapy (750 mg qd) for 5 days or amoxicillin/
clavulanate (875/125 mg bid) for 10 days.30 Significantly
more patients in the 5-day levofloxacin group had resolu-
tion of purulent sputum production (57.5% vs 35.6%;
P < 0.006), sputum production (65.4% vs 45.3%; P < 0.013),
and cough (60.0% vs 44.0%; P < 0.045), compared with the
amoxicillin/clavulanate group in the intent-to-treat (ITT)
population.30
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763 patients stratified by severity of illness, based on pre-
determined criteria and risk factors.38 In the uncompli-
cated group, patients were randomized to levofloxacin
(750 mg qd) for 3 days or azithromycin (500  1 d/250 mg
qd) for 5 days, while those in the complicated AECB group
received levofloxacin (750 mg qd) for 5 days or amoxicillin/
clavulanate (875/125 mg bid) for 10 days.38 In the uncom-
plicated group, Martinez and colleagues showed that both
clinical success and microbiological eradication rates in
microbiologically evaluable patients were superior for the
3-day levofloxacin regimen as compared with 5 days of
azithromycin (96.3% vs 87.4% and 93.8% vs 82.8%, respec-
tively). In the complicated cases, the clinical success and
microbiological eradication rates were similar for 5 days of
levofloxacin and 10 days of amoxicillin/clavulanate (81.4%
vs 80.9% and 81.4% vs 79.8%, respectively). The investiga-
tors concluded that short courses (3e5 days) of levofloxacin
750 mg are at least as effective as traditional courses of
azithromycin and amoxicillin/clavulanate for the spectrum
of patients with AECB.38
Short-course moxifloxacin therapy has also been inves-
tigated in AECB. A 5-day course of moxifloxacin was
explored in a randomized, multicenter study involving 936
patients with AECB that compared the efficacy of 5 days of
moxifloxacin (400 mg qd) to 10 days of moxifloxacin (400 mg
qd) or clarithromycin (500 mg bid). Overall, clinical reso-
lution was similar: 89% for 5-day moxifloxacin, 91% for 10-
day moxifloxacin, and 91% for 10-day clarithromycin.27
Bacteriological eradication rates at follow-up were also
comparable at 94%, 95%, and 91%, respectively. The 5-day
moxifloxacin therapy, however, has a favorable safety and
tolerability profile as compared to 10-day treatment with
moxifloxacin or clarithromycin; drug-related events were
reported for 26%, 30%, and 35%, respectively. The investi-
gators recommended that 5-day moxifloxacin is as effective
and furthermore, a more convenient treatment regimen
than a standard course of clarithromycin or a long duration
of moxifloxacin therapy for patients with AECB.27
Another clinical study of 563 patients compared 2
respiratory fluoroquinolones e levofloxacin and moxi-
floxacin e in the treatment of AECB. A 5-day, 400 mg qd
course of moxifloxacin was both clinically and microbio-
logically equivalent to a 7-day, 500 mg qd course of levo-
floxacin. Clinical success rates were achieved in 91.0% and
94.0% of patients in the moxifloxacin and levofloxacin
groups, respectively, while bacteriological eradication
rates were 92.8% and 93.8%, respectively.39
A randomized, nonblinded study including 162 patients
observed clinical success rates of 88.6% and 89.2% and
pathogen eradication rates at 14 days of 90.9% and 90.0% in
the 5-day moxifloxacin (400-mg tablet qd) and 7-day
amoxicillin/clavulanate (one, 625-mg tablet every 8 h)
groups, respectively.40 Similar results comparing a 5-day
course of moxifloxacin 400 mg qd to another short-course
therapy, 3-day azithromycin 500 mg qd, were reported by
Zervos et al.41 Of 342 patients randomized to either
treatment, clinical success rates for azithromycin and
moxifloxacin were comparable at days 10e12 (90% vs 90%)
and days 22e26 (81% vs 82%) in the ITT analysis. Further,
a similar safety and tolerability profile was observed in the
two short-course treatment groups.41MOSAIC was a large international study that compared
short- and long-term outcomes of antibiotic treatment of
AECB in patients with a history of heavy smoking and
significant COPD.32,42 Five-day moxifloxacin treatment was
compared with a 7e10-day course of amoxicillin, clari-
thromycin, or cefuroxime-axetil. The 5-day moxifloxacin
regimen demonstrated superior clinical cure rates and
higher bacteriological success rates than standard therapy
among the 730 patients enrolled.32,42 In the ITT population,
clinical cure was achieved in 70.9% of patients receiving
moxifloxacin compared with 62.8% given standard therapy
(95% CI, 1.4e14.9), while in the PP population those figures
were 69.7% and 62.1%, respectively (95% CI, 0.3e15.6).32
Higher bacteriologic eradication rates were observed in
the ITT population (76.8% vs 67.5%, respectively; 95% CI,
1.8e20.4) and in the microbiologically valid population
(91.5% vs 81.0%, respectively; 95% CI, 0.4e22.1).32 Multi-
variate analyses further confirmed the clinical cure benefit
(OR 1.49; 95% CI, 1.08e2.04) and clinical success (OR 1.57;
95% CI, 1.03e2.41) of short-course moxifloxacin compared
with standard therapy in patients with AECB.42
Short-course therapy with gemifloxacin has also been
investigated. A randomized, double-blind study was con-
ducted to compare 5-day oral gemifloxacin (320 mg qd)
with 7-day oral levofloxacin (500 mg qd) in 360 patients.
Gemifloxacin proved at least as effective as levofloxacin,
with clinical success rates at follow-up (days 14e21) in the
PP population of 88.2% for gemifloxacin and 85.1% for lev-
ofloxacin. Success rates at the long-term follow-up (days
28e35) were 83.7% and 78.4%, respectively.43
A 5-day course of gemifloxacin (320 mg qd) was compared
with 7 days of clarithromycin (500 mg bid) in a randomized,
double-blind study of 712 patients with AECB. Clinical
success rates were 85.4% and 84.6% for the gemifloxacin and
clarithromycin groups, respectively, and bacteriological
success rates were 86.7% and 73.1%, respectively.44 The
long-term health outcome of AECB recurrence also favored
short-course gemifloxacin. Significantly more patients
receiving gemifloxacin remained free of AECB recurrence
after 26 weeks compared with those receiving clari-
thromycin (71.0% vs 58.5%, respectively; P Z 0.016).44 File
et al. reported similar results comparing 5 days of gemi-
floxacin to 7 days of amoxicillin/clavulanate.45
Outcomes of antimicrobial therapy: speed of
recovery and relapse
Recovery after an exacerbation is influenced by the
severity of the exacerbation and the patient’s history of
exacerbations, including frequency of previous exacerba-
tions.6 Median recovery time after an episode is 6 days for
lung function and 7 days for symptoms.15 However,
recovery time may be considerably longer, as only 75% of
patients return to baseline peak flows 35 days after the
exacerbations have resolved.15 If the patient has not
improved after the first course of antibiotics, a second
course is indicated. Table 2 presents factors associated
with an increased risk of recurrence of AECB.1
When compared with standard therapy that involves
long-duration treatment (7 days) with non-fluo-
roquinolone regimens, 5-day fluoroquinolone therapy also
Figure 2 Improvement rate over the first 10 days of obser-
vation. Mean duration until improvement in moxifloxacin-
treated patients was 3.2 days compared with 4.5 days in
macrolide-treated patients. The difference of 1.2 days was
statistically significant (P < 0.0001).44 Reproduced with
permission from Schaberg T, Mo¨ller M, File T, Stauch K, Landen
H. Real-life treatment of acute exacerbations of chronic
bronchitis with moxifloxacin or macrolides: a comparative
post-marketing surveillance study in general practice. Clin
Drug Investig 2006; 26:733e44.
Table 2 Risk factors associated with increased recurrence
of AECB.
 Frequent purulent exacerbations.
 Poor underlying lung function.
 Lengthy duration of chronic obstructive lung disease.
 Chronic corticosteroid administration.
 Use of supplemental oxygen.
 Significant cardiac disease.
 Malnutrition.
Figure 1 Life-table analysis of time to the first composite
event (treatment failure, and/or new exacerbation, and/or
any further antibiotic treatment) stratified according to the
time of the last exacerbation prior to randomization to moxi-
floxacin or standard therapy.27 Reproduced with permission
from Wilson R, Allegra L, Huchon G, et al. Short-term and long-
term outcomes of moxifloxacin compared to standard antibi-
otic treatment in acute exacerbations of chronic bronchitis.
Chest 2004; 125:953e64.
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faster rate of recovery, lower relapse rate, and prolonged
relapse time intervals.28,29
Clinical studies have demonstrated improvements in
speed of recovery and relapse rate in AECB with short-
course fluoroquinolone therapy. In a study comparing 5-day
moxifloxacin therapy with 7-day ceftriaxone in 476
patients, moxifloxacin was associated with lower relapse
rates (23.3% vs 28.3%; P > 0.05) and shorter hospitalization
(137 days shorter than the control group treated with cef-
triaxone in inpatient plus day-hospital settings), resulting in
greater cost savings.29
The MOSAIC study also showed significantly improved
long-term outcomes in AECB with short-course fluo-
roquinolone therapy. Median times to new exacerbations in
patients who did not require further antibiotics were 131.0
days (mean Z 132.8 days) in the moxifloxacin group, and
103.5 days (meanZ 118.0 days) with standard therapy, the
difference was statistically significant (P Z 0.03).32 Addi-
tionally, a life-table analysis of time to the first composite
event (treatment failure, and/or new exacerbations, and/
or further antibiotic treatment) demonstrated a significant
difference favoring moxifloxacin for up to 5 months of
follow-up (PZ 0.03) (Fig. 1).32 For the elderly and patients
with >3 exacerbations in the previous year, the difference
was significant for 9 months in favor of moxifloxacin.42
Evidence from previously conducted Spanish studies also
indicates that recovery from AECB is faster in patients
treated with 5-day fluoroquinolone therapy.46,47 Time to
recovery was 20% shorter in one study, suggesting that
return to work or other activities could be hastened with
such treatment.46 In another study, 70.3% of patients
treated with a 5-day course of moxifloxacin recovered
within 5 days or less, compared with 44.4% of those treated
with co-amoxiclav or 49.7% treated with clarithromycin
(P < 0.0001).47 Moxifloxacin appeared to provide a protec-
tive effect against slow recovery as compared with co-
amoxiclav (OR 0.34; 0.26e0.45) and clarithromycin (OR
0.41; 0.31e2.85).47 In trials which compared real-life
treatment of AECB with moxifloxacin tablets to oral mac-
rolides, azithromycin, clarithromycin or roxithromycin, 5-
day moxifloxacin provides faster relief of symptoms and
higher recovery rates with comparable safety and tolera-
bility profiles (Fig. 2).48
The Gemifloxacin Long term Outcomes in Bronchitis
Exacerbations (GLOBE) study compared 5-day gemifloxacin
(320 mg qd) and 7-day clarithromycin (500 mg bid) on the
time for recovery of heath status, as measured by St.
George’s Respiratory Questionnaire (SGRQ) scores,
following an AECB.31 In 438 patients, the SGRQ scores didnot differ significantly between the two treatment groups
at baseline. However, the difference widened progressively
after treatment, and at 26 weeks, the SGRQ score was 4.6
units (95% CI, 9.1e0.1) lower in the gemifloxacin group,
suggesting that gemifloxacin may have a greater impact
than clarithromycin on the recovery of health status in
patients with AECB.31
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It is important to determine that an exacerbation is due to
bacterial infection before prescribing antibiotic therapy, as
40e60% of exacerbations are related to bacterial infec-
tions. The goals of therapy include rapidly resolving
patients’ symptoms, preventing relapse, prolonging the
time between exacerbations, interrupting the cycle of
recurrent infection, and reducing the extent of lung
damage. The most important decision is antibiotic choice.
Guidelines stratify patients by risk factor and disease
severity, and thus help improve selection of an appropriate
antibiotic and reduce treatment failures.
Studies of a variety of antimicrobial classes have
demonstrated that a shorter duration of therapy provides
comparable clinical outcomes to a standard, longer dosing
duration. In addition, short-course treatment regimens may
improve patient compliance, decrease the risk of adverse
events, lower costs, and possibly reduce the pressures that
drive antibiotic resistance.27 Research conducted on short-
course fluoroquinolone therapy supports its use. Further-
more, short-course, high-dose fluoroquinolone therapy also
demonstrates more rapid symptom resolution and faster
recovery rates than traditional therapy using non-fluo-
roquinolones for standard treatment durations. A 5-day
regimen for AECB has been approved by the US FDA for both
moxifloxacin (400 mg qd) and gemifloxacin (320 mg qd).
However, gemifloxacin 320 mg therapy has not been rec-
ommended by the Committee for Medicinal Products for
Human Use (CHMP) of EMEA.49
The demonstrations that 5-day fluoroquinolone therapy
is better than 7-day macrolide/b-lactam therapy, and that
5-day fluoroquinolone therapy is not worse than 7-day or
10-day fluoroquinolone (when stratified by severity),
support the recommendation of short-course, 5-day fluo-
roquinolone therapy as a treatment option for patients with
AECB.
Overall, short-course antibiotic therapy in exacerbations
of COPD and bronchitis is at least as effective as traditional
standard therapy in clinical success and microbiological
eradication rates. Additionally, short-course therapy is
associated with favorable safety and tolerability, and low-
ered risks of adverse events as compared with standard,
longer duration treatment. Moreover, in comparison with
long-duration non-fluoroquinolone treatment regiments,
short-course fluoroquinolone therapy also improved speed
of recovery, decreased relapse rate, prolonged recurrence
intervals, reduced hospitalization, shortened hospital stay,
and exhibited a beneficial impact on the long-term course
of the underlying chronic bronchitis or COPD. Short course
treatment is not recommended for patients with severe
lung disease that may have pseudomonas infection.
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